COVID-19 mRNA (Pfizer) vaccine Pregnancy and Breastfeeding Warnings
Brand names: Comirnaty, Pfizer-BioNTech COVID-19 Vaccine
Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.
COVID-19 mRNA (Pfizer) vaccine Pregnancy Warnings
The manufacturer makes no recommendation regarding use during pregnancy.
US FDA pregnancy category: Not assigned.
Risk summary: There are insufficient data available on use of this drug in pregnancy to inform a drug related risk.
Comments:
-A pregnancy exposure registry is available.
Animal studies of a dose equivalent to a single human dose given on 4 occasions (twice prior to mating and twice during gestation) showed no evidence of developmental harm to the fetus. There are no controlled data in human pregnancy.
To monitor the outcomes of pregnant women exposed to COVID-19 vaccines, a pregnancy registry has been established. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by visiting: https://c-viper.pregistry.com/
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
COVID-19 mRNA (Pfizer) vaccine Breastfeeding Warnings
The manufacturer makes no recommendation regarding use during lactation.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments:
-There is no information regarding this drug on the presence in human milk, the effects on a breastfed infant, or effects on milk production.
-The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.
See also
References for pregnancy information
- (2023) "Product Information. Comirnaty (2023-2024) PF (cvx 309) (SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 309))." Pfizer U.S. Pharmaceuticals Group
- (2024) "Product Information. Comirnaty (2024-2025) PF (cvx 309) (SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 309))." Pfizer U.S. Pharmaceuticals Group
References for breastfeeding information
- (2023) "Product Information. Comirnaty (2023-2024) PF (cvx 309) (SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 309))." Pfizer U.S. Pharmaceuticals Group
- (2024) "Product Information. Comirnaty (2024-2025) PF (cvx 309) (SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 309))." Pfizer U.S. Pharmaceuticals Group
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.